SCHEMBL10152859

SCHEMBL10152859

COc1ccc(NC(=O)OC(C)(C)C)cc1OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
GAA P10253 1/20 0.57
C5AR1 P21730 2/20 0.55
SMPD1 P17405 1/20 0.55
HDAC1 Q13547 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
MAPT P10636 2/20 0.55
LMNA P02545 1/20 0.55
ALOX12 P18054 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CTSV O60911 3/20 0.54
CTSL P07711 3/20 0.54
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TNF P01375 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5235275 0.87 BCHE (0.50) ALDH1A1GAAMAPTLMNACTSV
SCHEMBL20400859 0.86 NPC1 (0.51) GAAC5AR1CTSVCTSLMEN1
SCHEMBL9865221 0.86 FOLH1 (0.53) ALDH1A1GAAC5AR1L3MBTL1CTSV
SCHEMBL22502390 0.85 C5AR1 (0.62) ALDH1A1C5AR1SMPD1HDAC1HDAC8
SCHEMBL4199641 0.84 ALDH1A1 (0.57) ALDH1A1GAAMAPTLMNAKDM4E
SCHEMBL4041975 0.84 GAA (0.60) ALDH1A1GAAMAPTKDM4EMEN1
SCHEMBL10809983 0.83 ALDH1A1 (0.72) ALDH1A1GAAMAPTL3MBTL1KDM4E
SCHEMBL20418351 0.83 RAB9A (0.48) ALDH1A1GAAC5AR1MAPTCTSV
SCHEMBL29910105 0.83 PTPN1 (0.47) C5AR1NPC1RAB9ASMN1; SMN2CYP2C9
SCHEMBL29447700 0.83 RAB9A (0.48) ALDH1A1GAAC5AR1MAPTCTSV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230115176-A1 Complement Modulators and Related Methods RA PHARMACEUTICALS, INC. 2023-04-13 US disclosed
EP-3947352-A1 COMPLEMENT MODULATORS AND RELATED METHODS RA Pharmaceuticals, Inc. (US) 2022-02-09 EP disclosed
WO-2020205501-A1 COMPLEMENT MODULATORS AND RELATED METHODS RA PHARMACEUTICALS, INC. (US) 2020-10-08 WO disclosed
US-8148531-B2 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2012-04-03 US disclosed
US-8148531-B2 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2012-04-03 US disclosed
EP-1877383-B1 QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY CHROMA THERAPEUTICS LTD (GB) 2011-09-07 EP disclosed
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2009-05-21 US disclosed
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230115176-A1 Complement Modulators and Related Methods C5, C9, C1QBP ALDH1A1 4659/4885GAA 4067/4885C5AR1 12/4885
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CDK1, AURKC, CSNK1G3 ALDH1A1 2196/4885GAA 1657/4885C5AR1 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.